Experimental drug could help reduce brain damage, improve motor skills after stroke

September 21, 2012 by Alexis Blue
Ribbon structure of the drug 3K3A-APC, which researchers hope will help reduce brain damage in stroke victims. Credit: ZZ Biotech

(Medical Xpress)—A University of Arizona professor is overseeing the manufacture of an experimental drug that could help reduce brain damage after a stroke.

The drug, known as 3K3A-APC, currently is undergoing clinical trials in Europe to determine its safety in humans after proving effective in animal models at reducing brain damage and improving motor skills after a stroke when given in combination with another commonly used .

Thomas Davis, professor of pharmacology in the UA College of Medicine, was chosen to direct the manufacture of the drug for human trials after co-authoring a recent paper in the journal Stroke that pointed to the drug's effectiveness in rats and mice when used in conjunction with a clot-busting therapy known as , or tPA.

While tPA is commonly given to sufferers of , which results from an obstruction in a blood vessel supplying blood to the brain, the therapy poses significant challenges when administered alone, including a limited treatment window, Davis said.

"It has to be given within the first three to four and a half hours of the stroke," Davis said. "It only works in 10 percent of the patients, and it causes bleeding, so tPA alone isn't that effective."

Researchers now have found that 3K3A-APC, with its cell protective properties, may be effective in extending the treatment window for tPA while protecting against programmed cell death in the brain, which occurs when cellular signals convince to kill themselves following a stroke. When tested in rodents, the reduced by more than half, eliminated tPA-induced bleeding and significantly improved motor abilities.

The drug 3K3A-APC initially was created by a team of scientists at the Scripps Research Institute and the University of Southern California, led by John Griffin, professor at the Scripps Research Institute, and Dr. Berislav V. Zlokovic, director of the Neurogenic Institute at USC's Keck School of Medicine. It was further developed by Houston-based biotech company ZZ Biotech, for which Davis serves as a consultant and member of the scientific board of directors.

Davis worked closely with Griffin, Zlokovic and other collaborators to develop proper manufacturing procedures for the drug, which is being produced under Davis' direction by ZZ Biotech's contracted manufacturer, Laureate Biopharmaceuticals, in New Jersey.

The drug 3K3A-APC is a genetically engineered variant of the naturally occurring activated protein C, or APC, which helps regulate blood clots and inflammation in the body.

Previous research on naturally occurring APC, conducted by Griffin and Zlokovic, pointed to the protein's ability to prevent programmed in the brain. However, APC's natural blood-thinning properties posed a problem when considered as a treatment for stroke, since it might induce bleeding in the brain.

To address that problem, Griffin's hematology lab worked to develop an engineered variant of APC with fewer anticoagulant properties, and thus 3K3A-APC was born.

Davis was chosen to lead the production of the drug because of his extensive drug manufacturing experience and connection to ZZ Biotech.

Prior to joining the UA College of Medicine in 1980, Davis worked as a chemist for Abbot Pharmaceutical Co. Considered a premier investigator in the field of blood brain barrier research, Davis is widely regarded for changing the way drugs are designed and manufactured by pharmaceutical companies for brain delivery.

So far, no side effects have been shown in the initial clinical trials of 3K3A-APC in normal human subjects, Davis said, adding that he is prepared to manufacture more of the drug for future trials. "Starting next January, it will go into phase two clinical trials in patients as an adjuvant therapy, together with ."

Explore further: Experimental drug may extend therapeutic window for stroke

Related Stories

Experimental drug may extend therapeutic window for stroke

July 17, 2012
A team led by a physician-scientist at the University of Southern California (USC) has created an experimental drug that reduces brain damage and improves motor skills among stroke-afflicted rodents when given with federally ...

Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech

August 8, 2012
Clinical trials start this week for a stroke drug initially created by a team led by scientists at The Scripps Research Institute and the University of Southern California (USC), and further developed by biotech company ZZ ...

Clot-busting drug safe for stroke patients taking blood thinner

May 10, 2012
Acute ischemic stroke patients taking the blood thinner warfarin can be treated safely with the clot-busting drug tissue plasminogen activator (tPA), according to research presented at the American Heart Association's Quality ...

Hypothermia protects the brain against damage during stroke

March 6, 2012
Thromboembolic stroke, caused by a blood clot in the brain, results in damage to the parts of the brain starved of oxygen. Breaking up the clot with tissue plasminogen activator (tPA) reduces the amount of damage, however, ...

Recommended for you

Estrogen discovery could shed new light on fertility problems

December 12, 2017
Estrogen produced in the brain is necessary for ovulation in monkeys, according to researchers at the University of Wisconsin-Madison who have upended the traditional understanding of the hormonal cascade that leads to release ...

3-D printed microfibers could provide structure for artificially grown body parts

December 12, 2017
Much as a frame provides structural support for a house and the chassis provides strength and shape for a car, a team of Penn State engineers believe they have a way to create the structural framework for growing living tissue ...

Time of day affects severity of autoimmune disease

December 12, 2017
Insights into how the body clock and time of day influence immune responses are revealed today in a study published in leading international journal Nature Communications. Understanding the effect of the interplay between ...

Team identifies DNA element that may cause rare movement disorder

December 11, 2017
A team of Massachusetts General Hospital (MGH) researchers has identified a specific genetic change that may be the cause of a rare but severe neurological disorder called X-linked dystonia parkinsonism (XDP). Occurring only ...

Protein Daple coordinates single-cell and organ-wide directionality in the inner ear

December 11, 2017
Humans inherited the capacity to hear sounds thanks to structures that evolved millions of years ago. Sensory "hair cells" in the inner ear have the amazing ability to convert sound waves into electrical signals and transmit ...

Gene therapy improves immunity in babies with 'bubble boy' disease

December 9, 2017
Early evidence suggests that gene therapy developed at St. Jude Children's Research Hospital will lead to broad protection for infants with the devastating immune disorder X-linked severe combined immunodeficiency disorder. ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

wealthychef
not rated yet Sep 21, 2012
The article says tPA must be given within 3-4 hours of the stroke, implying APC is superior, but does not say how APC is superior to this if at all.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.